+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Helicobacter Pylori Non-invasive Testing Market - Global Forecast 2026-2032- Product Image
Helicobacter Pylori Non-invasive Testing Market - Global Forecast 2026-2032- Product Image
Sale

Helicobacter Pylori Non-invasive Testing Market - Global Forecast 2026-2032

  • Report

  • 198 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4904519
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Helicobacter Pylori Non-invasive Testing Market is projected to reach USD 332.29 Million in 2026. It is expected to continue growing at a CAGR of 7.73%, reaching USD 520.79 Million by 2032.

Helicobacter pylori non-invasive testing is becoming central to gastrointestinal care because H. pylori infection is one of the most common chronic bacterial infections worldwide and is a recognized cause of peptic ulcer disease, chronic gastritis, gastric mucosa-associated lymphoid tissue lymphoma, and gastric cancer. The World Health Organization and the International Agency for Research on Cancer classify H. pylori as a Group 1 carcinogen, reinforcing the clinical need for accurate detection, eradication monitoring, and population-level gastric cancer risk management.

The industry is shaped by rising use of urea breath tests, stool antigen tests, and laboratory-based serology in defined clinical pathways. Urea breath testing and monoclonal stool antigen testing are widely used to identify active infection, while post-treatment test-of-cure strategies are increasingly aligned with evidence-based gastroenterology guidelines, including recommendations to confirm eradication after therapy. Demand is expanding as health systems prioritize early diagnosis, antimicrobial stewardship, non-endoscopic testing options, and patient-friendly access across primary care, gastroenterology, and outpatient diagnostic settings.

Transformative Shifts Reshaping H. pylori Testing

The Helicobacter pylori non-invasive testing landscape is shifting from episodic diagnosis toward guideline-driven screening, confirmation, and treatment monitoring. Clinical practice has moved away from relying on symptoms alone because dyspepsia, peptic ulcer disease, and gastric cancer risk require objective testing. Non-invasive H. pylori diagnostics are also gaining relevance as endoscopy capacity remains limited in many health systems and payers seek lower-cost, scalable testing pathways for appropriate patients.

Another major shift is the growing emphasis on diagnostic accuracy and antibiotic resistance management. Consensus guidelines increasingly recommend confirming eradication after therapy, creating recurring demand for urea breath tests and stool antigen tests that detect active infection. At the same time, laboratories and diagnostic providers are investing in automation, digital ordering, sample logistics, electronic reporting, and integrated clinical workflows to reduce turnaround times and support primary care, gastroenterology, and public health programs.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence H. pylori non-invasive testing through workflow optimization, risk stratification, quality management, and decision support rather than replacing validated assays. AI-enabled systems can help identify patients who meet guideline-based testing criteria by analyzing electronic health records for dyspepsia, ulcer history, prior eradication therapy, gastric cancer risk factors, family history, medication exposure, and factors that may affect test performance, including proton pump inhibitors, antibiotics, and bismuth compounds.

The cumulative impact is strongest where AI is connected to laboratory information systems, population health platforms, and clinical decision support. Machine learning can support demand planning, flag incomplete test-of-cure follow-up, improve patient reminders, and assist laboratories in monitoring pre-analytical and operational quality indicators. However, adoption depends on transparent validation, data governance, regulatory oversight, and clinician trust, particularly because diagnostic decisions must remain anchored in analytically and clinically validated urea breath, stool antigen, serology, or molecular testing methods.

Key Regional Insights Across Global Markets

Asia-Pacific represents a high-priority region for Helicobacter pylori non-invasive testing due to large population size, substantial gastric cancer burden in several countries, and expanding access to outpatient diagnostics. Japan, South Korea, and China maintain strong clinical attention to gastric cancer prevention and digestive disease management, while India and Southeast Asian countries are improving diagnostic access through public and private healthcare expansion. North America continues to show strong demand through established gastroenterology guidelines, insurance coverage, centralized laboratories, digital ordering systems, and broad adoption of urea breath and stool antigen testing for active infection and eradication confirmation.

Latin America and Europe are advancing through improved diagnostic access and stronger adherence to evidence-based management of dyspepsia, peptic ulcer disease, and post-treatment confirmation. Europe benefits from consensus-led clinical practice, laboratory quality standards, and organized care pathways, while Latin America has meaningful opportunity as awareness, private diagnostic networks, and affordability improve. The Middle East is supported by healthcare infrastructure modernization, rising investment in hospital-based diagnostics, and growing use of non-invasive gastrointestinal testing, whereas Africa remains a long-term access opportunity where cost-effective stool antigen testing, decentralized sample collection, and clinician education can help address underdiagnosis and uneven laboratory availability.

Key Group Insights Across Economic and Policy Blocs

ASEAN markets are gaining momentum as urban healthcare access, private diagnostic networks, and awareness of gastrointestinal disease continue to improve across countries with diverse reimbursement and laboratory maturity. The GCC benefits from high healthcare spending, hospital modernization, specialist care expansion, and medical tourism, which support premium non-invasive H. pylori testing pathways. The European Union remains one of the most structured environments for H. pylori diagnostics due to harmonized quality expectations, clinician adoption of consensus recommendations, laboratory accreditation practices, and reimbursement frameworks in several member states.

BRICS economies combine large patient pools with rising diagnostic capacity, making them essential to long-term utilization of non-invasive testing for dyspepsia management, peptic ulcer disease, and gastric cancer risk reduction. G7 markets lead in guideline implementation, laboratory automation, digital health integration, and test-of-cure adoption, supporting higher-value diagnostic utilization. NATO countries overlap significantly with advanced European and North American healthcare systems, where procurement standards, clinical governance, interoperability, and secure health data infrastructure can accelerate adoption of accurate, non-invasive H. pylori testing solutions.

Key Country Insights for Priority Markets

The United States is a major market for Helicobacter pylori non-invasive testing because clinical guidelines support testing in dyspepsia, peptic ulcer disease, gastric mucosa-associated lymphoid tissue lymphoma, selected gastric cancer risk contexts, and post-treatment confirmation. Canada shows similar evidence-based adoption supported by primary care and specialist pathways, while Mexico and Brazil offer growth through expanding private laboratories, hospital networks, and broader access to affordable stool antigen and breath testing. In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from established clinical pathways, laboratory infrastructure, and evidence-based dyspepsia management, while Russia presents demand linked to gastric disease burden and ongoing laboratory modernization.

China and Japan are highly relevant because of gastric cancer prevention priorities, aging populations, and large-scale digestive disease management, with Japan maintaining strong clinical awareness of H. pylori eradication and post-treatment assessment. India offers significant long-term potential due to population size, high digestive disease presentation, and improving diagnostics access, although affordability, awareness, and standardized testing pathways remain important. Australia and South Korea demonstrate mature adoption patterns, supported by developed healthcare systems, gastroenterology expertise, clinical guideline use, and strong reliance on validated non-invasive testing for active infection and treatment follow-up.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated assays that detect active H. pylori infection, especially urea breath tests and monoclonal stool antigen tests, while clearly positioning serology for limited use cases where active infection confirmation is not required or where local clinical protocols support its use. Commercial and clinical strategies should emphasize guideline alignment, test-of-cure compliance, appropriate patient preparation, and education on factors that can cause false-negative results, including recent antibiotics, bismuth compounds, or proton pump inhibitor use.

Manufacturers, laboratories, and healthcare providers should invest in digital ordering, home sample collection where appropriate, patient reminders, clear pre-test instructions, and integrated reporting that supports treatment follow-up. Partnerships with gastroenterologists, primary care networks, payers, and public health stakeholders can expand appropriate utilization and reduce unnecessary endoscopy in suitable patients. In emerging markets, affordability, distribution reliability, sample stability, and clinician training will be decisive, while in mature markets differentiation will depend on accuracy, convenience, turnaround time, interoperability, and evidence demonstrating improved care pathway performance.

Research Methodology

This executive summary is based on secondary research from publicly available clinical guidelines, epidemiology literature, regulatory principles, healthcare policy sources, and peer-reviewed evidence on H. pylori diagnosis and management. Key inputs include global disease burden patterns, the established association between H. pylori and gastric cancer, and guideline-supported use of urea breath tests and stool antigen tests for active infection and eradication confirmation.

The analysis applies a triangulated research approach that evaluates clinical utility, diagnostic performance, market accessibility, regional healthcare infrastructure, reimbursement maturity, laboratory workflow trends, and technology adoption. Insights are framed for strategic decision-making and avoid unsupported market sizing, market share, or forecasting claims. All observations are aligned with evidence-based diagnostic practice and the known limitations of non-invasive testing modalities, including medication-related false negatives and the limited ability of serology to distinguish active from past infection.

Conclusion and Strategic Outlook

The Helicobacter pylori non-invasive testing industry is positioned for sustained strategic relevance as health systems focus on early diagnosis, gastric cancer risk reduction, peptic ulcer disease management, antimicrobial stewardship, and confirmation of eradication after therapy. Non-invasive approaches reduce dependence on endoscopy for many appropriate patients and support scalable gastrointestinal care across both mature and emerging healthcare environments.

Future competitiveness will depend on diagnostic accuracy, ease of use, reimbursement access, patient preparation, turnaround time, and integration into clinical workflows. Organizations that combine validated H. pylori testing with digital follow-up, clinician education, antimicrobial stewardship, and region-specific access models will be best positioned to meet clinical demand. As awareness rises, H. pylori non-invasive testing will remain a critical component of preventive gastroenterology and evidence-based digestive health management.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Helicobacter Pylori Non-invasive Testing Market, by Test Type
7.1. Introduction
7.2. Serology Test
7.2.1. IgG Antibody Test
7.2.2. IgA Antibody Test
7.2.3. IgM Antibody Test
7.3. Stool Antigen Test
7.3.1. Monoclonal Antibody Test
7.3.2. Polyclonal Antibody Test
7.4. Urea Breath Test
7.4.1. Carbon-13 Urea Breath Test
7.4.2. Carbon-14 Urea Breath Test
7.5. Molecular Test
7.6. Saliva Test
8. Helicobacter Pylori Non-invasive Testing Market, by Technology
8.1. Introduction
8.2. Immunoassay
8.2.1. Enzyme-Linked Immunosorbent Assay
8.2.2. Lateral Flow Immunoassay
8.2.3. Chemiluminescent Immunoassay
8.3. Infrared Spectrometry
8.4. Mass Spectrometry
8.5. Polymerase Chain Reaction
8.6. Biosensor
9. Helicobacter Pylori Non-invasive Testing Market, by Test Method
9.1. Introduction
9.2. Laboratory-Based Test
9.3. Point-Of-Care Test
10. Helicobacter Pylori Non-invasive Testing Market, by End User
10.1. Introduction
10.2. Clinics
10.3. Diagnostic Laboratories
10.4. Hospitals
11. Helicobacter Pylori Non-invasive Testing Market, by Mode Of Service
11.1. Introduction
11.2. Analyzer-Based Onsite Testing
11.3. Kit-Based Decentralized Testing
11.4. Central Laboratory Send-Out Testing
12. Helicobacter Pylori Non-invasive Testing Market, by Application
12.1. Introduction
12.2. Initial Diagnosis
12.3. Post-Treatment Confirmation
12.4. Population Screening
12.5. Antimicrobial Resistance Assessment
13. Helicobacter Pylori Non-invasive Testing Market, by Region
13.1. Asia-Pacific
13.2. Europe
13.3. North America
13.4. Latin America
13.5. Africa
13.6. Middle East
14. Helicobacter Pylori Non-invasive Testing Market, by Group
14.1. NATO
14.2. G7
14.3. European Union
14.4. BRICS
14.5. ASEAN
14.6. GCC
15. Helicobacter Pylori Non-invasive Testing Market, by Country
15.1. United States
15.2. China
15.3. Germany
15.4. Japan
15.5. India
15.6. United Kingdom
15.7. France
15.8. Canada
15.9. Australia
15.10. Brazil
15.11. Italy
15.12. Mexico
15.13. South Korea
15.14. Russia
15.15. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Abbott Laboratories
17.2. ACON Laboratories, Inc.
17.3. Applied Biotech, Inc.
17.4. Artron Laboratories Inc.
17.5. ARUP Laboratories
17.6. Bio-Rad Laboratories, Inc.
17.7. Biohit HealthCare Ltd.
17.8. Biohit Oyj
17.9. Biomerica, Inc.
17.10. CerTest Biotec S.L.
17.11. Coris BioConcept SPRL
17.12. CTK Biotech, Inc.
17.13. Danaher Corporation
17.14. DiaSorin S.p.A.
17.15. DRG International, Inc.
17.16. Epitope Diagnostics, Inc.
17.17. EUROIMMUN Medizinische Labordiagnostika AG
17.18. F. Hoffmann-La Roche AG
17.19. Guangzhou Wondfo Biotech Co., Ltd.
17.20. Hangzhou AllTest Biotech Co., Ltd.
17.21. Healgen Scientific LLC
17.22. Kibion AB
17.23. Laboratory Corporation Of America Holdings
17.24. Meridian Bioscience, Inc.
17.25. MP Biomedicals, LLC
17.26. Otsuka America Pharmaceutical, Inc.
17.27. Quest Diagnostics Incorporated
17.28. Sekisui Diagnostics, LLC
17.29. Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd.
17.30. Siemens Healthineers AG
17.31. Thermo Fisher Scientific Inc.
17.32. Trinity Biotech plc
17.33. Vircell, S.L.
17.34. Zhejiang Orient Gene Biotech Co., Ltd.
List of Figures
FIGURE 1. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 9. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST METHOD, 2025 VS 2032 (%)
FIGURE 11. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 13. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MODE OF SERVICE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MODE OF SERVICE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL SEROLOGY TEST MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL SEROLOGY TEST MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL SEROLOGY TEST MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL IGG ANTIBODY TEST MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL IGG ANTIBODY TEST MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL IGG ANTIBODY TEST MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL IGA ANTIBODY TEST MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL IGA ANTIBODY TEST MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL IGA ANTIBODY TEST MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL IGM ANTIBODY TEST MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL IGM ANTIBODY TEST MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL IGM ANTIBODY TEST MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL STOOL ANTIGEN TEST MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL STOOL ANTIGEN TEST MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL STOOL ANTIGEN TEST MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL MONOCLONAL ANTIBODY TEST MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL MONOCLONAL ANTIBODY TEST MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL MONOCLONAL ANTIBODY TEST MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL POLYCLONAL ANTIBODY TEST MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL POLYCLONAL ANTIBODY TEST MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL POLYCLONAL ANTIBODY TEST MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL UREA BREATH TEST MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL UREA BREATH TEST MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL UREA BREATH TEST MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL CARBON-13 UREA BREATH TEST MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL CARBON-13 UREA BREATH TEST MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL CARBON-13 UREA BREATH TEST MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL CARBON-14 UREA BREATH TEST MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL CARBON-14 UREA BREATH TEST MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL CARBON-14 UREA BREATH TEST MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL MOLECULAR TEST MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL MOLECULAR TEST MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL MOLECULAR TEST MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL SALIVA TEST MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL SALIVA TEST MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL SALIVA TEST MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL IMMUNOASSAY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL IMMUNOASSAY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL LATERAL FLOW IMMUNOASSAY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL LATERAL FLOW IMMUNOASSAY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL LATERAL FLOW IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL CHEMILUMINESCENT IMMUNOASSAY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL CHEMILUMINESCENT IMMUNOASSAY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL CHEMILUMINESCENT IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL INFRARED SPECTROMETRY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL INFRARED SPECTROMETRY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL INFRARED SPECTROMETRY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL BIOSENSOR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL BIOSENSOR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL BIOSENSOR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST METHOD, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL LABORATORY-BASED TEST MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL LABORATORY-BASED TEST MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL LABORATORY-BASED TEST MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL POINT-OF-CARE TEST MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL POINT-OF-CARE TEST MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL POINT-OF-CARE TEST MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MODE OF SERVICE, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL ANALYZER-BASED ONSITE TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL ANALYZER-BASED ONSITE TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL ANALYZER-BASED ONSITE TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL KIT-BASED DECENTRALIZED TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL KIT-BASED DECENTRALIZED TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL KIT-BASED DECENTRALIZED TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL CENTRAL LABORATORY SEND-OUT TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL CENTRAL LABORATORY SEND-OUT TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL CENTRAL LABORATORY SEND-OUT TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL INITIAL DIAGNOSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL INITIAL DIAGNOSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL INITIAL DIAGNOSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL POST-TREATMENT CONFIRMATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL POST-TREATMENT CONFIRMATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL POST-TREATMENT CONFIRMATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL POPULATION SCREENING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL POPULATION SCREENING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL POPULATION SCREENING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL ANTIMICROBIAL RESISTANCE ASSESSMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL ANTIMICROBIAL RESISTANCE ASSESSMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL ANTIMICROBIAL RESISTANCE ASSESSMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 106. ASIA-PACIFIC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 107. ASIA-PACIFIC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 108. ASIA-PACIFIC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2017-2032 (USD MILLION)
TABLE 109. ASIA-PACIFIC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2017-2032 (USD MILLION)
TABLE 110. ASIA-PACIFIC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, 2017-2032 (USD MILLION)
TABLE 111. ASIA-PACIFIC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 112. ASIA-PACIFIC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2017-2032 (USD MILLION)
TABLE 113. ASIA-PACIFIC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST METHOD, 2017-2032 (USD MILLION)
TABLE 114. ASIA-PACIFIC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 115. ASIA-PACIFIC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MODE OF SERVICE, 2017-2032 (USD MILLION)
TABLE 116. ASIA-PACIFIC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 117. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 118. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 119. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2017-2032 (USD MILLION)
TABLE 120. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2017-2032 (USD MILLION)
TABLE 121. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, 2017-2032 (USD MILLION)
TABLE 122. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 123. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2017-2032 (USD MILLION)
TABLE 124. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST METHOD, 2017-2032 (USD MILLION)
TABLE 125. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 126. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MODE OF SERVICE, 2017-2032 (USD MILLION)
TABLE 127. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 128. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 129. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 130. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2017-2032 (USD MILLION)
TABLE 131. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2017-2032 (USD MILLION)
TABLE 132. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, 2017-2032 (USD MILLION)
TABLE 133. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 134. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2017-2032 (USD MILLION)
TABLE 135. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST METHOD, 2017-2032 (USD MILLION)
TABLE 136. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 137. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MODE OF SERVICE, 2017-2032 (USD MILLION)
TABLE 138. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 139. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 140. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 141. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2017-2032 (USD MILLION)
TABLE 142. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2017-2032 (USD MILLION)
TABLE 143. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, 2017-2032 (USD MILLION)
TABLE 144. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 145. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2017-2032 (USD MILLION)
TABLE 146. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST METHOD, 2017-2032 (USD MILLION)
TABLE 147. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 148. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MODE OF SERVICE, 2017-2032 (USD MILLION)
TABLE 149. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 150. AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 151. AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 152. AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2017-2032 (USD MILLION)
TABLE 153. AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2017-2032 (USD MILLION)
TABLE 154. AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, 2017-2032 (USD MILLION)
TABLE 155. AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 156. AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2017-2032 (USD MILLION)
TABLE 157. AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST METHOD, 2017-2032 (USD MILLION)
TABLE 158. AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 159. AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MODE OF SERVICE, 2017-2032 (USD MILLION)
TABLE 160. AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 161. MIDDLE EAST HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 162. MIDDLE EAST HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 163. MIDDLE EAST HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2017-2032 (USD MILLION)
TABLE 164. MIDDLE EAST HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2017-2032 (USD MILLION)
TABLE 165. MIDDLE EAST HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, 2017-2032 (USD MILLION)
TABLE 166. MIDDLE EAST HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 167. MIDDLE EAST HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2017-2032 (USD MILLION)
TABLE 168. MIDDLE EAST HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST METHOD, 2017-2032 (USD MILLION)
TABLE 169. MIDDLE EAST HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 170. MIDDLE EAST HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MODE OF SERVICE, 2017-2032 (USD MILLION)
TABLE 171. MIDDLE EAST HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 172. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 173. NATO HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 174. NATO HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 175. NATO HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2017-2032 (USD MILLION)
TABLE 176. NATO HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2017-2032 (USD MILLION)
TABLE 177. NATO HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, 2017-2032 (USD MILLION)
TABLE 178. NATO HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 179. NATO HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2017-2032 (USD MILLION)
TABLE 180. NATO HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST METHOD, 2017-2032 (USD MILLION)
TABLE 181. NATO HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 182. NATO HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MODE OF SERVICE, 2017-2032 (USD MILLION)
TABLE 183. NATO HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 184. G7 HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 185. G7 HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 186. G7 HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2017-2032 (USD MILLION)
TABLE 187. G7 HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2017-2032 (USD MILLION)
TABLE 188. G7 HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, 2017-2032 (USD MILLION)
TABLE 189. G7 HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 190. G7 HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2017-2032 (USD MILLION)
TABLE 191. G7 HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST METHOD, 2017-2032 (USD MILLION)
TABLE 192. G7 HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 193. G7 HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MODE OF SERVICE, 2017-2032 (USD MILLION)
TABLE 194. G7 HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 195. EUROPEAN UNION HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 196. EUROPEAN UNION HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 197. EUROPEAN UNION HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2017-2032 (USD MILLION)
TABLE 198. EUROPEAN UNION HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2017-2032 (USD MILLION)
TABLE 199. EUROPEAN UNION HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, 2017-2032 (USD MILLION)
TABLE 200. EUROPEAN UNION HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 201. EUROPEAN UNION HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2017-2032 (USD MILLION)
TABLE 202. EUROPEAN UNION HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST METHOD, 2017-2032 (USD MILLION)
TABLE 203. EUROPEAN UNION HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 204. EUROPEAN UNION HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MODE OF SERVICE, 2017-2032 (USD MILLION)
TABLE 205. EUROPEAN UNION HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 206. BRICS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 207. BRICS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 208. BRICS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2017-2032 (USD MILLION)
TABLE 209. BRICS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2017-2032 (USD MILLION)
TABLE 210. BRICS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, 2017-2032 (USD MILLION)
TABLE 211. BRICS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 212. BRICS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2017-2032 (USD MILLION)
TABLE 213. BRICS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST METHOD, 2017-2032 (USD MILLION)
TABLE 214. BRICS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 215. BRICS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MODE OF SERVICE, 2017-2032 (USD MILLION)
TABLE 216. BRICS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 217. ASEAN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 218. ASEAN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 219. ASEAN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2017-2032 (USD MILLION)
TABLE 220. ASEAN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2017-2032 (USD MILLION)
TABLE 221. ASEAN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, 2017-2032 (USD MILLION)
TABLE 222. ASEAN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 223. ASEAN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2017-2032 (USD MILLION)
TABLE 224. ASEAN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST METHOD, 2017-2032 (USD MILLION)
TABLE 225. ASEAN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 226. ASEAN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MODE OF SERVICE, 2017-2032 (USD MILLION)
TABLE 227. ASEAN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 228. GCC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 229. GCC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 230. GCC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2017-2032 (USD MILLION)
TABLE 231. GCC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2017-2032 (USD MILLION)
TABLE 232. GCC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, 2017-2032 (USD MILLION)
TABLE 233. GCC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 234. GCC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2017-2032 (USD MILLION)
TABLE 235. GCC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST METHOD, 2017-2032 (USD MILLION)
TABLE 236. GCC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 237. GCC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MODE OF SERVICE, 2017-2032 (USD MILLION)
TABLE 238. GCC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 239. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 240. UNITED STATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 241. UNITED STATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 242. UNITED STATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2017-2032 (USD MILLION)
TABLE 243. UNITED STATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2017-2032 (USD MILLION)
TABLE 244. UNITED STATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, 2017-2032 (USD MILLION)
TABLE 245. UNITED STATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 246. UNITED STATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2017-2032 (USD MILLION)
TABLE 247. UNITED STATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST METHOD, 2017-2032 (USD MILLION)
TABLE 248. UNITED STATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 249. UNITED STATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MODE OF SERVICE, 2017-2032 (USD MILLION)
TABLE 250. UNITED STATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 251. CHINA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 252. CHINA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 253. CHINA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2017-2032 (USD MILLION)
TABLE 254. CHINA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2017-2032 (USD MILLION)
TABLE 255. CHINA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, 2017-2032 (USD MILLION)
TABLE 256. CHINA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 257. CHINA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2017-2032 (USD MILLION)
TABLE 258. CHINA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST METHOD, 2017-2032 (USD MILLION)
TABLE 259. CHINA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 260. CHINA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MODE OF SERVICE, 2017-2032 (USD MILLION)
TABLE 261. CHINA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 262. GERMANY HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 263. GERMANY HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 264. GERMANY HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2017-2032 (USD MILLION)
TABLE 265. GERMANY HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2017-2032 (USD MILLION)
TABLE 266. GERMANY HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, 2017-2032 (USD MILLION)
TABLE 267. GERMANY HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 268. GERMANY HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2017-2032 (USD MILLION)
TABLE 269. GERMANY HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST METHOD, 2017-2032 (USD MILLION)
TABLE 270. GERMANY HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 271. GERMANY HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MODE OF SERVICE, 2017-2032 (USD MILLION)
TABLE 272. GERMANY HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 273. JAPAN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 274. JAPAN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 275. JAPAN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2017-2032 (USD MILLION)
TABLE 276. JAPAN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2017-2032 (USD MILLION)
TABLE 277. JAPAN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, 2017-2032 (USD MILLION)
TABLE 278. JAPAN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 279. JAPAN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2017-2032 (USD MILLION)
TABLE 280. JAPAN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST METHOD, 2017-2032 (USD MILLION)
TABLE 281. JAPAN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 282. JAPAN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MODE OF SERVICE, 2017-2032 (USD MILLION)
TABLE 283. JAPAN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 284. INDIA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 285. INDIA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 286. INDIA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2017-2032 (USD MILLION)
TABLE 287. INDIA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2017-2032 (USD MILLION)
TABLE 288. INDIA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, 2017-2032 (USD MILLION)
TABLE 289. INDIA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 290. INDIA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2017-2032 (USD MILLION)
TABLE 291. INDIA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST METHOD, 2017-2032 (USD MILLION)
TABLE 292. INDIA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 293. INDIA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MODE OF SERVICE, 2017-2032 (USD MILLION)
TABLE 294. INDIA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 295. UNITED KINGDOM HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 296. UNITED KINGDOM HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 297. UNITED KINGDOM HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2017-2032 (USD MILLION)
TABLE 298. UNITED KINGDOM HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2017-2032 (USD MILLION)
TABLE 299. UNITED KINGDOM HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, 2017-2032 (USD MILLION)
TABLE 300. UNITED KINGDOM HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 301. UNITED KINGDOM HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2017-2032 (USD MILLION)
TABLE 302. UNITED KINGDOM HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST METHOD, 2017-2032 (USD MILLION)
TABLE 303. UNITED KINGDOM HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 304. UNITED KINGDOM HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MODE OF SERVICE, 2017-2032 (USD MILLION)
TABLE 305. UNITED KINGDOM HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 306. FRANCE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 307. FRANCE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 308. FRANCE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2017-2032 (USD MILLION)
TABLE 309. FRANCE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2017-2032 (USD MILLION)
TABLE 310. FRANCE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, 2017-2032 (USD MILLION)
TABLE 311. FRANCE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MI

Companies Mentioned

  • Abbott Laboratories
  • ACON Laboratories, Inc.
  • Applied Biotech, Inc.
  • Artron Laboratories Inc.
  • ARUP Laboratories
  • Bio-Rad Laboratories, Inc.
  • Biohit HealthCare Ltd.
  • Biohit Oyj
  • Biomerica, Inc.
  • CerTest Biotec S.L.
  • Coris BioConcept SPRL
  • CTK Biotech, Inc.
  • Danaher Corporation
  • DiaSorin S.p.A.
  • DRG International, Inc.
  • Epitope Diagnostics, Inc.
  • EUROIMMUN Medizinische Labordiagnostika AG
  • F. Hoffmann-La Roche AG
  • Guangzhou Wondfo Biotech Co., Ltd.
  • Hangzhou AllTest Biotech Co., Ltd.
  • Healgen Scientific LLC
  • Kibion AB
  • Laboratory Corporation Of America Holdings
  • Meridian Bioscience, Inc.
  • MP Biomedicals, LLC
  • Otsuka America Pharmaceutical, Inc.
  • Quest Diagnostics Incorporated
  • Sekisui Diagnostics, LLC
  • Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech plc
  • Vircell, S.L.
  • Zhejiang Orient Gene Biotech Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages198
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 332.29 Million
Forecasted Market Value ( USD ) by 2032 $ 520.79 Million
Compound Annual Growth Rate7.7%
Regions CoveredGlobal
No. of Companies Mentioned34

Related Topics

Related Reports

Helicobacter Pylori Diagnostics Market - Global Forecast 2026-2032 - Product Image

Helicobacter Pylori Diagnostics Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
Non-invasive Helicobacter Pylori Testing - Global Strategic Business Report - Product Image

Non-invasive Helicobacter Pylori Testing - Global Strategic Business Report

  • Report
  • 176 Pages
  • Global
From
Helicobacter Pylori Diagnostics - Global Strategic Business Report - Product Image

Helicobacter Pylori Diagnostics - Global Strategic Business Report

  • Report
  • 249 Pages
  • Global
From
Helicobacter Pylori Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Helicobacter Pylori Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 181 Pages
  • Global
From
Helicobacter Pylori Testing Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Helicobacter Pylori Testing Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 172 Pages
  • Global
From

About the Helicobacter Pylori Non Invasive Testing Market

Within the realm of infectious disease testing, Helicobacter pylori (H. pylori) non-invasive testing plays a crucial role in the detection of the bacterium H. pylori, which is known to cause various gastrointestinal conditions, including gastritis, ulcers, and certain types of stomach cancer. Non-invasive testing methods are particularly advantageous as they can be administered without the need for endoscopic procedures. These tests include urea breath tests, stool antigen tests, and serological tests that detect antibodies against H. pylori in the blood. The market for H. pylori non-invasive testing is comprised of various test products that cater to the needs of different healthcare settings, from hospitals to clinics and even home testing environments. The development of accurate and user-friendly test kits allows for timely diagnosis and treatment, which is crucial in managing H. pylori-related infections. Moreover, advancements in testing technology have led to the improvement of test sensitivity and specificity, making non-invasive tests a reliable alternative to invasive diagnostic methods. Some companies operating within the H. pylori non-invasive testing market include DiaSorin, Thermo Fisher Scientific, Meridian Bioscience, Bio-Rad Laboratories, and Abbott Laboratories. These companies offer a range of products designed to detect H. pylori infection with varying methods of analysis, contributing to advances in non-invasive diagnostics and expanding the options available for healthcare providers and their patients. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.